Pharmacokinetics (PK)
Pharmacokinetics (PK) describes what the body does to a compound: absorption, distribution, metabolism, and excretion (often abbreviated as ADME). It is the study of how a substance moves through the body over time.
The Four Pillars of PK
Absorption
The process by which a compound enters the body from its site of administration. Key considerations include:
- Route of administration: Intravenous (bypasses absorption), subcutaneous, intramuscular, oral, nasal, transdermal, etc.
- Rate and extent: How quickly and how much of the compound reaches systemic circulation
- Bioavailability: The fraction of administered dose that reaches circulation (100% for IV, variable for other routes)
Distribution
How the compound disperses throughout body tissues and fluids. Factors include:
- Volume of distribution (Vd): A theoretical volume that relates the amount of compound in the body to its plasma concentration
- Protein binding: Many compounds bind to plasma proteins, affecting their free (active) concentration
- Tissue permeability: The ability to cross barriers like the blood-brain barrier or cell membranes
- Lipophilicity: Lipophilic compounds tend to distribute into fatty tissues
Metabolism
The biochemical transformation of the compound, primarily in the liver:
- Enzymatic breakdown: Enzymes such as cytochrome P450 modify compounds
- Peptide degradation: Peptides are often broken down by proteases and peptidases in blood and tissues
- Metabolites: The breakdown products, which may be active or inactive
- First-pass metabolism: Significant metabolism before reaching systemic circulation (especially for oral administration)
Excretion
The removal of the compound and its metabolites from the body:
- Renal excretion: Elimination through urine (common for small molecules)
- Biliary excretion: Elimination through feces
- Other routes: Minor elimination through sweat, saliva, breath, or breast milk
Key PK Parameters
Researchers measure several standard values to characterize PK:
- Half-life (t1/2): Time for concentration to decrease by 50%
- Cmax: Maximum concentration achieved in plasma
- Tmax: Time at which Cmax occurs
- AUC: Area Under the Curve—total exposure over time
- Clearance (CL): Volume of plasma cleared of substance per unit time
- Bioavailability (F): Percentage of administered dose reaching systemic circulation
PK vs. PD
While pharmacokinetics describes what the body does to the drug, pharmacodynamics (PD) describes what the drug does to the body. Both are essential for understanding a compound’s full profile:
| Pharmacokinetics (PK) | Pharmacodynamics (PD) |
|---|---|
| Absorption | Receptor binding |
| Distribution | Signal transduction |
| Metabolism | Downstream effects |
| Excretion | Response magnitude |
| Concentration over time | Effect over time |
Relevance to Peptide Research
PK studies are particularly important for peptides because:
- Rapid degradation: Many peptides have short half-lives due to enzymatic breakdown
- Route-dependent profiles: Subcutaneous administration often produces different PK than IV
- Modification effects: Chemical modifications intended to improve therapeutic properties often alter PK characteristics
- Species differences: PK in animal models may not translate directly to humans
- Dosing implications: Understanding PK helps determine appropriate dosing intervals
PK Studies in Research Design
PK research typically involves:
- Serial blood sampling to measure concentration over time
- Analysis by techniques like mass spectrometry or ELISA
- Mathematical modeling to describe and predict behavior
- Comparison between formulations or administration routes
- Assessment of variability between individuals
Note: PK measures exposure, not effect. A compound may have favorable PK (stable concentrations) but limited or undesired PD (biological effects), or conversely, strong effects but very short exposure.